Global Alliance to Accelerate Pharmacogenomic Discovery
The goal of the PGRN-RIKEN collaboration is to accelerate pharmacogenomic discovery through collaborative research that makes use of well-phenotyped pharmacogenomic samples and genomewide or NextGen sequencing methods. PGRN members who have DNA samples collected from patients on various drugs with associated therapeutic or adverse drug response phenotype may apply for a PGRN-RIKEN collaborative study. The study enables collaboration with researcher at RIKEN Center for Integrative Medical Sciences (IMS). The approved study will allow the samples to be genotyped on a genomewide genotyping platform or sequenced at no cost.
種々の薬剤の治療効果や薬剤副作用などの表現型を有する患者さんのDNAサンプルを所有するPGRNのメンバーは、PGRNとRIKENの連携研究に応募することが可能です。共同研究は、理化学研究所統合生命医科学研究センター(RIKEN Center for Integrative Medical Sciences (IMS))の研究者と共同で実施されます。採択された研究課題は、ゲノムワイド関連解析、あるいはシークエンス解析における遺伝子型測定が無料で実施されます。
Each year, we have two rounds for submitting proposal. The PGRN-RIKEN Round 16 call for proposals is now closed. Please visit here in future for future call.
Each year, we have two meeting, alternating between San Francisco and Tokyo. The next meeting is September 7th-8th 2017 in San Francisco, USA. Please register here by Friday, August 11. There is a registration fee to attend the meeting, please visit the registration fee payment site here.
We have 46 funded projects, 57publications and over 52,000 DNA samples genotyped through this collaboration.
Click on a circle to see the name of the project.
The size of the circle corresponds to the approximate number of samples in each study.
The lines between the circles represent shared PIs.
The GAP-J (currently known as PGRN-RIKEN) was formally launched in the Spring of 2008. PGRN-RIKEN (previously known as GAP-J) was the brainchild of Dr. Yusuke Nakamura, Former Director of the RIKEN, and Drs. Mark J. Ratain and Kathleen M. Giacomini, Principal Investigators in the PGRN. After a series of discussions on the need to accelerate discoveries in pharmacogenomics, Drs. Nakamura, Ratain and Giacomini decided to try to utilize the complementary resources and expertise of the PGRN and the RIKEN (see GAP-J Letter of Intent). The PGRN has been successful assembling an abundance of DNA samples from well-phenotyped patients for specific drugs and drug combinations. The RIKEN focuses on high-throughput services for SNP analysis and has developed extraordinarily powerful genomewide technologies to identify genes that determine susceptibility to various disease and response to treatment. Together, the PGRN-RIKEN capitalizes on these strength to advance discoveries in personalized medicines and benefit global populations.
Since 2012, Drs. Giacomini, Kubo and Ratain have co-lead the PGRN-RIKEN collaborative studies. This study was supported by the NIH Pharmacogenomics Research Network (PGRN)-RIKEN Global Alliance (U19 GM061390, 2010 – 2015).